m6A-centered Crosstalk Information
Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
| Crosstalk ID |
M6ACROT05813
|
[1] | |||
m6A modification
KCNQ1OT1
KCNQ1OT1
METTL14
Methylation
 : m6A sites
Direct
Enhancement
Non-coding RNA
KCNQ1OT1
miR-7-5p
lncRNA miRNA circRNA
|
|||||
| m6A Modification: | |||||
|---|---|---|---|---|---|
| m6A Regulator | Methyltransferase-like 14 (METTL14) | WRITER | |||
| m6A Target | KCNQ1 opposite strand/antisense transcript 1 (KCNQ1OT1) | ||||
| Epigenetic Regulation that have Cross-talk with This m6A Modification: | |||||
| Epigenetic Regulation Type | Non-coding RNA (ncRNA) | ||||
| Epigenetic Regulator | KCNQ1 opposite strand/antisense transcript 1 (KCNQ1OT1) | LncRNA | View Details | ||
| Regulated Target | hsa-miR-7-5p | View Details | |||
| Crosstalk Relationship | m6A → ncRNA | Enhancement | |||
| Crosstalk Mechanism | m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA | ||||
| Crosstalk Summary | METTL14 promotes doxorubicin-induced cardiomyocyte ferroptosis by regulating the KCNQ1 opposite strand/antisense transcript 1 (KCNQ1OT1)-hsa-miR-7-5p-TFRC axis. | ||||
| Responsed Drug | Doxorubicin | ||||
| Cell Process | Ferroptosis | ||||
In-vitro Model |
AC16 [Human hybrid cardiomyocyte] | Normal | Homo sapiens | CVCL_4U18 | |
| In-vivo Model | Male Sprague-Dawley rats (6-8 weeks old; weighed from 210 to 230 g) were purchased from HFK Bioscience Co. Ltd. They were housed under standard laboratory conditions. Rats were randomly assigned to four groups (n = 6 per group). The first was the control group, which were treated daily with 0.5 ml of 0.9% saline by intraperitoneal injection for 14 days, and there were three DOX model groups, which were treated three times weekly with 2.5 mg/kg of DOX by intraperitoneal injection for 14 weeks. At day 14, mice in the DOX model groups were infected through an intramyocardial injection of either control shNC or shMettl14 (1 × 109 titer) at three distinct locations in the left ventricular free wall three times a week for 2 weeks, and they were treated daily with 30 mg/kg of ferroptosis inducer erastin (MedChemExpress, USA) through intragastric administration or vehicle control (Saline) for 2 weeks. | ||||